We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLSM:NASDAQPulsenmore Ltd. Analysis

Data as of 2026-04-24 - not real-time

$3.37

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Pulsenmore Ltd. (PLSM) trades at $3.37, well below its DCF‑derived fair value of roughly $44, indicating a deep discount. The 20‑day SMA sits just above the current price, while the 50‑day and 200‑day SMAs are higher, confirming a short‑term bearish bias. RSI at just under 40 points to near‑oversold conditions, suggesting a possible rebound. MACD shows a bullish signal as the line sits above the signal line, with a small positive histogram. Volume is trending upward, yet average daily volume remains modest, underscoring limited liquidity. Volatility over the past 30 days exceeds 70%, reflecting price swings.
The company reports zero revenue and negative margins, with a trailing EPS of –$0.82, highlighting ongoing profitability challenges. Nonetheless, free cash flow is positive, and the remote‑ultrasound market in Europe and Israel offers a growth runway. Beta is low (~0.16), indicating low sensitivity to broader market moves, while the Fear & Greed Index signals “Extreme Greed,” implying heightened speculative appetite. The support level at $3 aligns with the current price, but the nearest resistance near $3.93 could cap upside in the near term. Given the mix of deep valuation discount, technical signs of a bounce, and sector‑specific risks, investors should weigh upside potential against liquidity and regulatory uncertainties.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering at immediate support around $3
  • Bearish trend indicated by SMA hierarchy
  • Rising volume but overall low liquidity

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Significant undervaluation versus DCF fair value
  • Bullish MACD crossover suggesting momentum shift
  • Growth opportunity in remote ultrasound diagnostics

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑run market potential for tele‑ultrasound devices
  • Low beta reducing systematic market risk
  • Extreme Greed sentiment may fuel speculative upside

Key Metrics & Analysis

Financial Health

Revenue Growth578.30%
Profit Margin-39.61%
ROE-17.62%
ROA-6.24%
Debt/Equity1.88
Free Cash Flow$7.7M
Industry P/E25.4

Technical Analysis

TrendBearish
RSI40.0
Support$3.00
Resistance$3.93
MA 20$3.53
MA 50$4.12
MA 200$4.59
MACDBullish
VolumeIncreasing
Fear & Greed Index88.02

Valuation

Fair Value$43.60
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.16
Volatility72.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.